Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Share-based Compensation (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Share-based Compensation for 5 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 34.58% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Dec 2025, up 52.02% year-over-year, with the annual reading at $22.1 million for FY2025, 52.02% up from the prior year.
  • Share-based Compensation hit $5.7 million in Q4 2025 for ARS Pharmaceuticals, up from $5.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.7 million in Q4 2025 to a low of -$11.2 million in Q4 2021.
  • Historically, Share-based Compensation has averaged $2.7 million across 5 years, with a median of $3.5 million in 2024.
  • Biggest five-year swings in Share-based Compensation: plummeted 93.84% in 2022 and later surged 752.27% in 2023.
  • Year by year, Share-based Compensation stood at -$11.2 million in 2021, then skyrocketed by 142.51% to $4.8 million in 2022, then crashed by 52.17% to $2.3 million in 2023, then surged by 87.14% to $4.3 million in 2024, then skyrocketed by 34.58% to $5.7 million in 2025.
  • Business Quant data shows Share-based Compensation for SPRY at $5.7 million in Q4 2025, $5.7 million in Q3 2025, and $5.4 million in Q2 2025.